Use of antithrombotic therapy in the management of factor XI deficiency: is it safe?
Uso de terapia antitrombótica en el manejo de la deficiencia del factor XI: ¿es segura?
Abstract
Factor XI (FXI) deficiency represents a paradigm of unpredictable bleeding risk. However, emerging population-based evidence and accumulated clinical series consistently indicate that antithrombotic therapy can be administered with an acceptable safety profile. Clinical practice should rely on individualized risk stratification and the judicious selection of therapeutic agents, accompanied by regular clinical and laboratory monitoring. A shortage of prospective studies remains—particularly those including severe cases, comparing different anticoagulants, and assessing patient-centered outcomes. The naturally observed phenomenon supports the development of drugs targeting FXI/FXIa as a promising pathway toward anticoagulation with reduced bleeding risk. The most recent evidence invites the hematology and cardiovascular communities to transform a molecular “rarity” into an opportunity to rethink hemostasis and, perhaps, redefine the standard of antithrombotic therapy in selected populations.
Downloads
Published
2025-12-15
How to Cite
Hernández-Vides , K. M., Ardila-Quiñones , M. E., Blanco-Arenas , A. V., Avila-Galeano, A. C., & Ortega-Sierra, M. (2025). Use of antithrombotic therapy in the management of factor XI deficiency: is it safe? Uso de terapia antitrombótica en el manejo de la deficiencia del factor XI: ¿es segura?. Peruvian Journal of Health Care and Global Health, 9(3). Retrieved from http://revista.uch.edu.pe/index.php/hgh/article/view/366
Issue
Section
Letters to the editor
License
Copyright (c) 2025 Karen Margarita Hernández Vides , Manuel Enrique Ardila Quiñones , Andrea Valentina Blanco Arenas , Angie Camila Avila Galeano, Michael Ortega Sierra
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The authors will retain their copyright and will guarantee to the journal right of first publication of their work, which will simultaneously be under a Creative Commons Attribution 4.0 License that allows third parties to share the work whenever attribuying their author and first publication in this journal.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post online a pre-publication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
